| HOME >> BIOLOGY >> TECHNOLOGY |
ZP1846 is useful prevention and/or treatment of an unmet medical need like chemotherapy-induced diarrhoea, which may prevent discontinuation and dose modification during cancer chemotherapy. The compound has been partnered with Helsinn.
ZP1848 is a novel paradigm for the treatment of Inflammatory Bowel Diseases (e.g. Crohn's Disease). The compound is in late preclinical development.
In addition, Zealand Pharma has a rich and broad portfolio of pre-clinical projects targeting a variety of disease areas, including osteoporosis and obesity-related diabetes.
Zealand Pharma is based in Copenhagen and has approximately 65 employees.
The Company's investors include BankInvest Biomedical Venture, LD Pensions, Dansk Erhvervsinvestering and Sunstone Capital as well as the leading international biotech investors CDC Innovation and AGF Private Equity (both in Paris) and LSP (Amsterdam).
Contact:
Helsinn Healthcare SA
Roberto De Ponti, Senior Director,
Head of Business Development & Licensing In
Tel.: +41-91-985-21-21
E-Mail: info-hhc@helsinn.com
Internet:http://www.helsinn.com
Zealand Pharma A/S
Mogens Vang Rasmussen
Executive Vice President
Chief Operating Officer and Chief Financial Officer IT & Communications
Zealand Pharma A/S
Smedeland 26 B
DK-
'/>"/>
| SOURCE Helsinn Healthcare SA Copyright©2008 PR Newswire. All rights reserved |